

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint

☒ Practitioner(s) named with the Customer Number:

45511

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ OR

The address associated with Customer Number:

45511

☐ OR

Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

Assignee Name and Address:

Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse, Belgium B-2340

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/95 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE OF Assignee of Record

The individual whose signature and title is applied below is authorized to act on behalf of the assignee

Signature

Name

Title

Mary A. Appollina
Mary A. Appollina

Proxy Holder

Date

Telephone

5-13-05

732-524-3742

This collection of information is required by 37 CFR 1.51, 1.52 and 1.53. The information is required to assist or obtain a benefit of the public which is to be (and by the USPTO to review) an application. Confidentiality is provided by 35 USC, 122 and 37 CFR 1.61 and 1.62. The collection is authorized to take 30 minutes to complete, including gathering, preparing, and recording the completed application form in the USPTO. Time may vary depending upon the individual case. Any comments on the quality of this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND PERS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

If you need assistance in completing this form, call 1-800-PTO-9150 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: FREYNE, et al.

Confirmation No: 5134

Application No.: 10/564,844

Group Art Unit: 1624

Filing Date: JANUARY 13, 2006

Examiner: SUSANNA MOORE

Title: TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE
KINASE 3 INHIBITORS

STATEMENT UNDER 37 CFR § 3.73(b)


JANSSEN PHARMACEUTICA N.V., a CORPORATION, states:

- ☒ that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application.
- ☒ The assignment was recorded in the Patent and Trademark Office at Reel 017499, Frame 0045.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date:

3/20/07



Name: S. Maurice Valla
Attorney for Applicant
Registration No. 43, 996

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439